DNeuro Biosciences is a clinical-stage biotechnology company developing the first disease modifying, regenerative therapy for diabetic peripheral neuropathy (DPN).
Today’s standard of care for DPN focuses on symptom control, leaving the underlying nerve damage unaddressed. DNeuro is changing that paradigm. Our proprietary combination regenerative platform targets the root biological drivers of neuropathy, including neuroinflammation, microvascular damage, and impaired nerve repair.

Our lead program, DNeuro Tx, integrates three scientifically validated compounds delivered through a patent-pending, patient-friendly delivery system designed for long-term use. Early human proof-of-concept and pilot data demonstrate meaningful improvements in pain, sensation, nerve conduction, mobility, and quality of life.

DNeuro is advancing a robust clinical pipeline across diabetic neuropathy and related neurological and vascular indications, supported by a global IP strategy and a clear regulatory pathway.

Our mission is to restore nerve function and quality of life for millions, shifting care from pain management to true recovery.

DNeuro Biosciences

Org chart

Teams

Offices